These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 18681090

  • 1. Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthma.
    Pearlman DS, Greos L, LaForce C, Orevillo CJ, Owen R, Higgins M.
    Ann Allergy Asthma Immunol; 2008 Jul; 101(1):90-5. PubMed ID: 18681090
    [Abstract] [Full Text] [Related]

  • 2. Tolerability of indacaterol, a novel once-daily beta2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study.
    Yang WH, Martinot JB, Pohunek P, Beier J, Magula D, Cameron R, Owen R, Higgins M.
    Ann Allergy Asthma Immunol; 2007 Dec; 99(6):555-61. PubMed ID: 18219838
    [Abstract] [Full Text] [Related]

  • 3. Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study.
    LaForce C, Alexander M, Deckelmann R, Fabbri LM, Aisanov Z, Cameron R, Owen R, Higgins M.
    Allergy; 2008 Jan; 63(1):103-11. PubMed ID: 18053019
    [Abstract] [Full Text] [Related]

  • 4. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison.
    Rennard S, Bantje T, Centanni S, Chanez P, Chuchalin A, D'Urzo A, Kornmann O, Perry S, Jack D, Owen R, Higgins M.
    Respir Med; 2008 Jul; 102(7):1033-44. PubMed ID: 18479895
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of indacaterol, a new 24-hour beta2-agonist, in patients with asthma: a dose-ranging study.
    Kanniess F, Boulet LP, Pierzchala W, Cameron R, Owen R, Higgins M.
    J Asthma; 2008 Dec; 45(10):887-92. PubMed ID: 19085578
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B.
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma.
    Brookman LJ, Knowles LJ, Barbier M, Elharrar B, Fuhr R, Pascoe S.
    Curr Med Res Opin; 2007 Dec; 23(12):3113-22. PubMed ID: 17999782
    [Abstract] [Full Text] [Related]

  • 8. Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma.
    Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, van As A.
    Eur Respir J; 2007 May; 29(5):871-8. PubMed ID: 17251236
    [Abstract] [Full Text] [Related]

  • 9. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.
    Beier J, Chanez P, Martinot JB, Schreurs AJ, Tkácová R, Bao W, Jack D, Higgins M.
    Pulm Pharmacol Ther; 2007 May; 20(6):740-9. PubMed ID: 17088091
    [Abstract] [Full Text] [Related]

  • 10. Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases.
    Beeh KM, Beier J.
    Adv Ther; 2009 Jul; 26(7):691-9. PubMed ID: 19609496
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study.
    Kinoshita M, Lee SH, Hang LW, Ichinose M, Hosoe M, Okino N, Prasad N, Kramer B, Fukuchi Y, Indacaterol Asian COPD Study Investigators.
    Respirology; 2012 Feb; 17(2):379-89. PubMed ID: 22122202
    [Abstract] [Full Text] [Related]

  • 12. 24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma: comparison with placebo and formoterol.
    LaForce C, Korenblat P, Osborne P, Dong F, Higgins M.
    Curr Med Res Opin; 2009 Oct; 25(10):2353-9. PubMed ID: 19650753
    [Abstract] [Full Text] [Related]

  • 13. Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study.
    Chuchalin AG, Tsoi AN, Richter K, Krug N, Dahl R, Luursema PB, Cameron R, Bao W, Higgins M, Woessner R, van As A.
    Respir Med; 2007 Oct; 101(10):2065-75. PubMed ID: 17643277
    [Abstract] [Full Text] [Related]

  • 14. Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease.
    Vogelmeier C, Magnussen H, LaForce C, Owen R, Kramer B.
    Ther Adv Respir Dis; 2011 Oct; 5(5):345-57. PubMed ID: 21719531
    [Abstract] [Full Text] [Related]

  • 15. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease.
    van Noord JA, Buhl R, Laforce C, Martin C, Jones F, Dolker M, Overend T.
    Thorax; 2010 Dec; 65(12):1086-91. PubMed ID: 20978028
    [Abstract] [Full Text] [Related]

  • 16. 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol.
    Bauwens O, Ninane V, Van de Maele B, Firth R, Dong F, Owen R, Higgins M.
    Curr Med Res Opin; 2009 Feb; 25(2):463-70. PubMed ID: 19192991
    [Abstract] [Full Text] [Related]

  • 17. Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients.
    Van de Maele B, Fabbri LM, Martin C, Horton R, Dolker M, Overend T.
    COPD; 2010 Dec; 7(6):418-27. PubMed ID: 21166630
    [Abstract] [Full Text] [Related]

  • 18. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
    Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B, INHANCE Study Investigators.
    Am J Respir Crit Care Med; 2010 Jul 15; 182(2):155-62. PubMed ID: 20463178
    [Abstract] [Full Text] [Related]

  • 19. Indacaterol Novartis/skyePharma.
    Currie GP.
    Curr Opin Investig Drugs; 2006 May 15; 7(5):457-63. PubMed ID: 16729723
    [Abstract] [Full Text] [Related]

  • 20. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design.
    Barnes PJ, Pocock SJ, Magnussen H, Iqbal A, Kramer B, Higgins M, Lawrence D.
    Pulm Pharmacol Ther; 2010 Jun 15; 23(3):165-71. PubMed ID: 20080201
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.